πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs
7,238

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Page 23 of 151

  1. BMN 044 IV 6 mg/kg

    BioMarin Pharmaceutical Australia Pty Ltd

    Duchenne Muscular Dystrophy

    phase 2 small molecule terminated

    1 trial

  2. BMN 110

    BioMarin Pharmaceutical Australia Pty Ltd

    Mucopolysaccharidosis IVA

    phase 2 small molecule terminated

    3 trials

  3. BMN 110

    BioMarin Pharmaceutical Australia Pty Ltd

    MPS IV A

    phase 2 small molecule terminated

    2 trials

  4. BMN 165 (rAvPAL-PEG)

    BioMarin Pharmaceutical Australia Pty Ltd

    Phenylketonuria

    phase 2 mab completed

    1 trial

  5. BMN 190

    BioMarin Pharmaceutical Australia Pty Ltd

    Jansky-Bielschowsky Disease

    phase 2 mab completed

    2 trials

  6. BMN 190 recombinant human tripeptidyl peptidase-1 (rhTPP1)

    BioMarin Pharmaceutical Australia Pty Ltd

    Jansky-Bielschowsky Disease

    phase 2 mab completed

    1 trial

  7. BMN 307

    BioMarin Pharmaceutical Australia Pty Ltd

    Phenylketonuria (PKU)

    phase 2 small molecule active

    1 trial

  8. BMN 351

    BioMarin Pharmaceutical Australia Pty Ltd

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  9. BMN 351

    BioMarin Pharmaceutical Australia Pty Ltd

    Duchenne Muscular Dystrophy (DMD)

    phase 2 small molecule active

    1 trial

  10. BMN 701

    BioMarin Pharmaceutical Australia Pty Ltd

    Pompe Disease

    phase 2 mab completed

    2 trials

  11. BMS-945429 Placebo

    CSL Behring GmbH

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  12. BMS-955176

    ViiV Healthcare B.V.

    HIV Infections

    phase 2 small molecule terminated

    1 trial

  13. BMS-986165

    Bristol-Myers Squibb

    Granulomatous Colitis

    phase 2 small molecule terminated

    1 trial

  14. BMS-986165

    Bristol-Myers Squibb

    Lupus Nephritis

    phase 2 small molecule terminated

    1 trial

  15. BMS-986165

    Bristol-Myers Squibb

    Systemic Lupus Erythematosus

    phase 2 small molecule completed

    1 trial

  16. BMS-986466

    Bristol-Myers Squibb

    Advanced Solid Tumors

    phase 2 small molecule terminated

    1 trial

  17. BMS-986470, BMS-986470, N/A, BMS-986470

    Bristol-Myers Squibb Australia Pty Ltd

    Sickle Cell Disease

    phase 2 small molecule active

    1 trial

  18. BMS-986504

    Bristol-Myers Squibb

    Solid Tumors

    phase 2 small molecule active

    1 trial

  19. BMS-986517

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  20. BMS-986523, BMS-986523

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Solid Tumor Malignancies

    phase 2 small molecule active

    1 trial

  21. BMS-986525, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Bristol-Myers Squibb Australia Pty Ltd

    Relapsed/Refractory Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  22. BMSC transplantation

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Liver Cirrhosis

    phase 2 other active

    1 trial

  23. BNT111

    Regeneron UK Limited

    Melanoma Stage III

    phase 2 mab completed

    1 trial

  24. BNT111, LIBTAYO 350 mg concentrate for solution for infusion.

    BioNTech SE

    Melanoma (Stage III and IV)

    phase 2 small molecule active

    1 trial

  25. BNT116

    Regeneron UK Limited

    Advanced Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  26. BNT116, LIBTAYO 350 mg concentrate for solution for infusion.

    Lacuna Pharma Pty Ltd

    Advanced Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  27. BNT142

    BioNTech SE

    Solid Tumors

    phase 2 small molecule active

    1 trial

  28. BNT327 1-15, BNT327, BNT326

    BioNTech SE

    Advanced solid tumors

    phase 2 small molecule active

    1 trial

  29. BNT327 50 mg ml, BNT327 20 mg ml, IPILIMUMAB, ATEZOLIZUMAB, ATEZOLIZUMAB, BEVACIZUMAB, Ipilimumab

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced or unresectable Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  30. BNT327, BNT314, BNT327 1-15

    BioNTech SE

    Metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  31. BNT327, BNT323

    BioNTech SE

    Advanced Breast Cancer Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  32. BNT327, BNT324

    BioNTech SE

    Advanced Lung Cancer

    phase 2 small molecule active

    1 trial

  33. BNT327, DOCETAXEL

    BioNTech SE

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  34. BNT329

    BioNTech SE

    Advanced Solid Cancers

    phase 2 small molecule active

    1 trial

  35. BOOST cells

    The George Institute

    Osteogenesis Imperfecta (OI) type III and severe type IV. Severe type of congenital Brittle bone disease.

    phase 2 small molecule active

    1 trial

  36. BOTOX 100 Allergan Units Powder for Solution for Injection

    Disc Medicine

    postoperative pancreatic fistulas

    phase 2 small molecule active

    1 trial

  37. BOTULINUM TOXIN , -

    The George Institute

    Myogenous temporomandibular disorders (TMDM)

    phase 2 small molecule active

    1 trial

  38. BPF-CCRT (run-in)

    Hospital Authority, Hong Kong

    Stage III Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  39. BPS804

    Mereo BioPharma Group plc

    Chronic-kidney Disease Stage 5D on Stable Hemodialysis

    phase 2 small molecule terminated

    1 trial

  40. BPS804

    Mereo BioPharma Group plc

    Osteogenesis Imperfecta

    phase 2 small molecule terminated

    1 trial

  41. BPS804

    Ultragenyx UK Limited

    Osteogenesis Imperfecta

    phase 2 small molecule completed

    1 trial

  42. BPS804

    Mereo BioPharma Group plc

    Hypophosphatasia

    phase 2 small molecule completed

    1 trial

  43. BPS804 20mg/Kg

    Mereo BioPharma Group plc

    Osteopenia

    phase 2 small molecule completed

    1 trial

  44. BRENSOCATIB, MOMETASONE , BRENSOCATIB, The placebo used the same excipients as that used in IMP without active drug substance. The placebo was developed as film-coated tablet same in size and appearance to the IMP.

    Insmed Limited

    Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)

    phase 2 small molecule active

    1 trial

  45. BRIGATINIB, Alunbrig 180 mg film-coated tablets, Alunbrig 90 mg film-coated tablets, Alunbrig 30 mg film-coated tablets

    AXIM BIOTECHNOLOGIES, INC.

    Anaplastic Large Cell Lymphoma (ALCL), Inflammatory Myofibroblastic Tumors (IMT), Other solid tumors

    phase 2 small molecule active

    1 trial

  46. BRII-179

    Vir Biotechnology

    For Treatment of Chronic Hepatitis B Virus Infection

    phase 2 mab active

    1 trial

  47. BRII-835 (VIR-2218)

    Vir Biotechnology

    Hepatitis B, Chronic

    phase 2 small molecule completed

    1 trial

  48. BRONCHO-VAXOM Children Capsules placebo, BRONCHO-VAXOM, 3,5mg, kapsuΕ‚ki

    Lacuna Pharma Pty Ltd

    Recurrent wheezing

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources Β· All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.